×
Baxter Cash on Hand 2010-2024 | BAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Baxter cash on hand for the quarter ending September 30, 2024 was
$1.420B
, a
75.47% decline
year-over-year.
Baxter cash on hand for 2023 was
$3.194B
, a
85.91% increase
from 2022.
Baxter cash on hand for 2022 was
$1.718B
, a
41.78% decline
from 2021.
Baxter cash on hand for 2021 was
$2.951B
, a
20.88% decline
from 2020.
View More
Baxter Cash on Hand 2010-2024 | BAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Baxter cash on hand for 2023 was
$3.194B
, a
85.91% increase
from 2022.
Baxter cash on hand for 2022 was
$1.718B
, a
41.78% decline
from 2021.
Baxter cash on hand for 2021 was
$2.951B
, a
20.88% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$203.2B
Stryker (SYK)
$148.2B
Boston Scientific (BSX)
$133.1B
EssilorLuxottica (ESLOY)
$113.5B
Medtronic (MDT)
$109B
Haleon (HLN)
$42.9B
Lonza Group Ag (LZAGY)
$42.1B
GE HealthCare Technologies (GEHC)
$37.7B
ResMed (RMD)
$35B
Terumo (TRUMY)
$29.2B
Koninklijke Philips (PHG)
$24.4B
Zimmer Biomet Holdings (ZBH)
$22.1B
Insulet (PODD)
$18.4B
Smith & Nephew SNATS (SNN)
$11.2B
BellRing Brands (BRBR)
$9.5B
Bio-Rad Laboratories (BIO)
$9B
Demant (WILYY)
$8.3B
Lantheus Holdings (LNTH)
$5.5B
TG Therapeutics (TGTX)
$4.7B
Haemonetics (HAE)
$4.3B
ICU Medical (ICUI)
$4.2B
Prestige Consumer Healthcare (PBH)
$4.1B
Perrigo (PRGO)
$3.7B
Envista Holdings (NVST)
$3.5B
Neogen (NEOG)
$3.3B
Agios Pharmaceuticals (AGIO)
$3.1B
Shandong Weigao Medical Polymer (SHWGF)
$3B
GN Store Nord (GNNDY)
$2.8B
QuidelOrtho (QDEL)
$2.6B
Warby Parker (WRBY)
$2.3B